1-4 of 4
Christian J. Chatelain, MD
Close
Sort by
Journal Articles

Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture

Hélène Haguet, MSc, Jonathan Douxfils, Christian J. Chatelain, MD, Carlos Graux, Francois Mullier, PharmD, Jean-Michel Dogné
Journal: Blood
Blood (2017) 130 (Supplement 1): 1591.
https://doi.org/10.1182/blood.V130.Suppl_1.1591.1591
Published: 2017
Journal Articles

In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions

Hélène Haguet, MSc, Jonathan Douxfils, Christian J. Chatelain, MD, Carlos Graux, Francois Mullier, PharmD, Jean-Michel Dogné
Journal: Blood
Blood (2017) 130 (Supplement 1): 1592.
https://doi.org/10.1182/blood.V130.Suppl_1.1592.1592
Published: 2017
Journal Articles

Transfer of Multidrug Resistance Among Acute Myeloid Leukemia Cells Via Extracellular Vesicles and Their Micrornas Cargo

Céline Bouvy, PhDStudent, Adeline Wannez, PhDStudent, Christian J. Chatelain, MD, Jean-Michel Dogné, Pharm.D PhD
Journal: Blood
Blood (2016) 128 (22): 2864.
https://doi.org/10.1182/blood.V128.22.2864.2864
Published: 2016
Journal Articles

BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival

Jonathan Douxfils, Pharm.D PhDCandidate, Hélène Haguet, MSc, Christian J. Chatelain, MD, Carlos Graux, MDPhD, Jean-Michel Dogné, Pharm.D PhD
Journal: Blood
Blood (2015) 126 (23): 2785.
https://doi.org/10.1182/blood.V126.23.2785.2785
Published: 2015